MedC Biopharma is a clinical-stage company developing a novel treatment for cutaneous T-cell lymphoma, a type of skin cancer that afflicts 100,000 new patients annually.The company's R&D is based on a combined effort of Professor Hinanit Koltai, the head of medical cannabis research at the national lab in ARO, Israel, and Professor Emmilia Hodek, director of Dermatology, Rabin Medical Center, Israel.

The company's R&D pipeline includes two additional skin oncology indications and anxiety-related indications.